Singleron launches single cell eQTL analysis as part of their sequencing service
A new bioinformatic pipeline to investigate single cell eQTL analysis is now offered in the sequencing service from Singleron Biotechnologies.
Cologne, Germany, 25th January 2023
Source: Singleron Biotechnologies GmbH
Bioinformatic experts at Singleron Biotechnologies, a leader in single cell sequencing, have developed a new single cell eQTL analysis workflow that takes advantage of single cell RNA sequencing (scRNAseq) and whole genome sequencing (WGS) data to predict cell-type specific eQTLs.
eQTL (expression Quantitative Trait Loci) are specific variants regulating expression levels of local or distant genes. eQTL analysis, aims to predict the association between genetic variation and gene expression levels, to elucidate the relationship between gene regulation and phenotypic traits.
This resource is ideal for customers wanting to perform population studies and requires both wet lab and computational support for single cell eQTL analysis and adds a valuable addition in understanding the molecular mechanisms of disease. It will complement the already established single cell multi-omics sequencing service from Singleron, to provide customers requiring an outsourced solution for their single cell sequencing.
Samples are globally accepted to laboratories in Cologne, Germany, and Singapore, where single cell experts with extensive knowledge in both wet lab and data analysis, will support customers to produce a streamlined workflow for their projects.
Founded in 2018, Singleron develops and commercializes single-cell multi-omics products that can be used in both research and clinical settings. Its current product portfolio includes instruments, microfluidic devices, reagents, software analysis and database solutions that facilitate high-throughput single-cell analysis. The company currently has offices, laboratories, and manufacturing facilities in Germany, Singapore, China, and the US. Its products are used in over 2,000 laboratories in hospitals, research institutes, and pharmaceutical companies.
Copyright © 2024 Singleron Biotechnologies